ACC 2016: Recent Advances to Improve Outcomes for Patients with Dyslipidemia
This Official Elsevier Medical Meeting Reporter will cover data presented at the American College of Cardiology 65th Annual Scientific Session and Expo held in Chicago, Illinois on April 2-4, 2016. The four expert faculty will communicate imperative information for clinical decision-making, as it relates to the comprehensive healthcare team, in both the initiation of treatment and effective communication of therapeutic options with the patient. Criteria for statin intolerance and familial hypercholesterolemia will be reviewed in order to ensure physicians are making informed decisions. At the conclusion of this program, learners should be able to create individualized treatment plans incorporating PCSK9 Inhibitors to both reduce risk and improve outcomes in their dyslipidemia patients.
This activity has been designed to meet the educational needs of cardiologists, internists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with dyslipidemia.
Upon completion of this activity, participants will be better able to:
- Review the diagnostic and patient assessment criteria for statin intolerance and familial hypercholesterolemia in patients with dyslipidemia.
- Examine clinical trial data of current and emergent PCSK9 inhibitors for the treatment of dyslipidemia.
- Formulate personalized treatment plans to incorporate PCSK9 inhibitors to reduce risk and improve outcomes for patients with dyslipidemia.
|Christopher P. Cannon, MD|
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Michael Blaha, MD
Jorge Plutzky, MD
Paul Ridker, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Christopher Cannon, MD|
Grant/Research Support: Arisaph Pharmaceuticals, Inc; AstraZeneca; Bristol-Myers Squibb Company; Boehringer-Ingelheim GmbH; GlaxoSmithKline; Janssen Global Services, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.
Consultant/Advisor: Alnylam Pharmaceuticals, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer-Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; Kowa American Corporation; Lipomedix; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceuticals U.S.A., Inc.
Michael Blaha, MD
Consultant/Advisor: Akcea Therapeutics and Novartis AG
Jorge Plutzky, MD
Consultant/Advisor: Amgen Inc.; AstraZeneca; Genzyme Corporation; GlaxoSmithKline; Merck & Co., Inc.; Pfizer Inc.; sanofi-aventis U.S. LLC.
|Paul Ridker, MD|
Consultant/Advisor: Amgen Inc.; AstraZeneca; Boston Heart Diagnostics Corporation; Eli Lilly and Company; Ionis Pharmaceuticals
Grant/Research Support: AstraZeneca; Novartis AG; Pfizer Inc.
Royalties/Patents: AstraZeneca; Siemens AG
Non-faculty: Sandy Breslow; Alison Kemp; Leah Johnson; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Nicole Brestowski; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the last 12 months.
This CME activity has been supported by an independent educational grant from Amgen Inc.
Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.
CME Credit (Physicians)
The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education to provide continuing education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com. Additional information on the process of converting AMA PRA Category 1 Credits™ to ECMECs® can be found at: www.eaccme.eu.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician